Related Experiment Video

Updated: Mar 23, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

8.0K

Genetic Variants in MicroRNAs Predict Recurrence of Ischemic Stroke

Zhizhong Zhang1, Gelin Xu1, Biyang Cai1

  • 1Department of Neurology, Jinling Hospital, Medical School of Nanjing University, 305# East Zhongshan Road, Nanjing, 210002, Jiangsu, China.

Molecular Neurobiology
|March 25, 2016
PubMed

Insights

Genetic variations in microRNAs, specifically miR-618 SNP rs2682818, are linked to increased ischemic stroke recurrence risk. This microRNA variant is an independent prognostic factor for stroke outcomes.

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • MicroRNAs regulate crucial brain functions, including development and neurogenesis.
  • Aberrant microRNA expression is implicated in ischemic stroke pathogenesis.
  • Genetic variations within microRNAs may influence stroke clinical behavior.

Purpose of the Study:

  • To investigate the association between common functional microRNA single nucleotide polymorphisms (SNPs) and ischemic stroke.
  • To determine if these genetic variations impact the age of stroke onset and recurrence risk.

Main Methods:

  • Genotyping of six common functional microRNA SNPs (miR-146a, miR-149, miR-196a2, miR-499, miR-605, and miR-618) in 914 ischemic stroke patients.
  • Statistical analysis, including log-rank tests and multivariate Cox regression, to assess associations with onset age and recurrence.

Main Results:

  • MicroRNA variants were not associated with the age of ischemic stroke onset.
  • The miR-618 rs2682818 variant (GT/TT genotypes) significantly increased the risk of ischemic stroke recurrence (HR=1.72, P=0.006).
  • This association was more pronounced in patients with small-vessel disease and the variant was an independent prognostic factor.

Conclusions:

  • The miR-618 SNP rs2682818 may be a significant genetic factor influencing ischemic stroke recurrence.
  • This finding highlights the potential role of microRNA genetics in stroke prognosis and management.
Keywords:
MicroRNAsPolymorphismStroke

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.8K
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

6.0K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.2K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.6K
MicroRNAs01:22

MicroRNAs

12.0K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
108
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
87